Hsiu-O Ho - 臺北醫學大學

查看斯高帕斯 (Scopus) 概要

電子郵件hsiuohotmu.edutw

h-index

每年研究成果

學歷

1992 臺北醫學大學藥學博士
1985 臺北醫學大學藥學碩士
1983 臺北醫學大學藥學學士

經歷

2012 臺北醫學大學藥物科學學科教授
2003-2012 臺北醫學大學藥學系教授

研究興趣

藥物分析
藥物傳遞系統

指紋

查看啟用 Hsiu-O Ho 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。

1 類似的個人檔案

12 已完成

開發熱安定性醣化PLGA奈米顆粒負載以SARS-CoV-2 spike protein編碼的mRNA作為新型冠狀病毒疫苗之研究
Ho, H.-O. (PI)
8/1/22 → 7/31/23
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
發展可標靶樹突細胞之mPEG-PLGA/PLGA-PEG-PLGA混和水膠體的奈米顆粒癌症疫苗用於癌症免疫療法(3/3)
Ho, H.-O. (PI)
8/1/21 → 7/31/22
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
發展可標靶樹突細胞之mPEG-PLGA/PLGA-PEG-PLGA混和水膠體的奈米顆粒癌症疫苗用於癌症免疫療法(2/3)
Ho, H.-O. (PI)
8/1/20 → 7/1/21
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
發展可標靶樹突細胞之mPEG-PLGA/PLGA-PEG-PLGA混和水膠體的奈米顆粒癌症疫苗用於癌症免疫療法(1/3)
Ho, H.-O. (PI)
8/1/19 → 7/31/20
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
開發可遞送粒細胞-巨噬細胞集落刺激因子(GM-CSF)的注射型溫感性水膠載體於癌症免疫療法之應用
Ho, H.-O. (PI)
8/1/18 → 7/1/19
研究計畫: A - 政府部門 › b - 國家科學及技術委員會

151 文章
2 評論/辯論
1 會議貢獻
1 回顧型文獻
更多
- 1 專利

Bioactive matrix scaffold of oxidized sacchachitin via green catalyst of siliacat tempo for enhancing bone regeneration
Sheu, M. T., Lin, S. Y., Cheng, W. J., Lin, H. L., Hsieh, C. M., Ho, H. O., Chen, L. C. & Wu, M. H., 12月 2024, 於: Carbohydrate Polymer Technologies and Applications. 8, 100576.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids
Chou, P. Y., Lai, M. J., Tsai, K. K., Cheng, L. H., Wu, Y. W., Chen, M. C., Pan, S. L., Ho, H. O., Nepali, K. & Liou, J. P., 2024, (接受/付印) 於: Journal of Medicinal Chemistry. 67, 19, p. 17207-17225 19 p.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
1 引文斯高帕斯（Scopus）
Composite Hydrogels of Ultrasound-Assisted-Digested Formic Acid-Decellularized Extracellular Matrix and Sacchachitin Nanofibers Incorporated with Platelet-Rich Plasma for Diabetic Wound Treatment
Lin, C. J., Lin, H. L., You, W. C., Ho, H. O., Sheu, M. T., Chen, L. C. & Cheng, W. J., 8月 2023, 於: Journal of Functional Biomaterials. 14, 8, 423.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
4 引文斯高帕斯（Scopus）
Synergistic Combination of Irinotecan and Rapamycin Orally Delivered by Nanoemulsion for Enhancing Therapeutic Efficacy of Pancreatic Cancer
Liu, Y. H., Chen, L. C., Cheng, W. T., Wei, P. S., Hsieh, C. M., Sheu, M. T., Lin, S. Y., Ho, H. O. & Lin, H. L., 2月 2023, 於: Pharmaceutics. 15, 2, 473.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
1 引文斯高帕斯（Scopus）
Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy
Cheng, W. J., Chuang, K. H., Lo, Y. J., Chen, M., Chen, Y. J., Roffler, S. R., Ho, H. O., Lin, S. Y. & Sheu, M. T., 1月 2022, 於: Journal of Controlled Release. 344, p. 235-248 14 p.
研究成果: 雜誌貢獻 › 文章 › 同行評審
13 引文斯高帕斯（Scopus）

Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer
Hsieh, C.-M. (Contributor), Chen, L.-C. (Contributor), Liu, D.-Z. (Contributor), Ho, H.-O. (Contributor), Su, C.-Y. (Contributor), Sheu, M.-T. (Contributor), Jhan, H.-J. (Contributor) & Chang, C.-E. (Contributor), Unknown Publisher, 2018
DOI: 10.6084/m9.figshare.5908795, https://doi.org/10.6084%2Fm9.figshare.5908795
資料集: Dataset
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Su, C.-Y. (Contributor), Chen, M. (Contributor), Chen, L.-C. (Contributor), Ho, Y.-S. (Contributor), Ho, H.-O. (Contributor), Lin, S.-Y. (Contributor), Chuang, K.-H. (Contributor) & Sheu, M.-T. (Contributor), Unknown Publisher, 5月 2 2018
DOI: 10.6084/m9.figshare.6213620.v1, https://tandf.figshare.com/articles/Bispecific_antibodies_anti-mPEG_anti-HER2_for_active_tumor_targeting_of_docetaxel_DTX_-loaded_mPEGylated_nanocarriers_to_enhance_the_chemotherapeutic_efficacy_of_HER2-overexpressing_tumors/6213620/1
資料集: Dataset
Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
Chen, L.-C. (Contributor), Lin, S.-Y. (Contributor), Sheu, M.-T. (Contributor), Ho, Y.-S. (Contributor), Su, C.-Y. (Contributor), Chen, M. (Contributor), Ho, H.-O. (Contributor) & Chuang, K.-H. (Contributor), Unknown Publisher, 2018
DOI: 10.6084/m9.figshare.6213620, https://doi.org/10.6084%2Fm9.figshare.6213620
資料集: Dataset
Novel application of pluronic lecithin organogels (PLOs) for local delivery of synergistic combination of docetaxel and cisplatin to improve therapeutic efficacy against ovarian cancer
Chang, C.-E. (Contributor), Hsieh, C.-M. (Contributor), Chen, L.-C. (Contributor), Su, C.-Y. (Contributor), Liu, D.-Z. (Contributor), Jhan, H.-J. (Contributor), Ho, H.-O. (Contributor) & Sheu, M.-T. (Contributor), Unknown Publisher, 1月 1 2018
DOI: 10.6084/m9.figshare.5908795.v1, https://tandf.figshare.com/articles/Novel_application_of_pluronic_lecithin_organogels_PLOs_for_local_delivery_of_synergistic_combination_of_docetaxel_and_cisplatin_to_improve_therapeutic_efficacy_against_ovarian_cancer/5908795/1
資料集: Dataset